Precision Medicine

With its new SmartBioSurface slides, Italian firm Tethis aims to solve a major lab challenge. The key? A nanotech surface that could reshape disease research.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

SciSparc's subsidiary just spent nearly C$10M on a quantum computing firm. This is the operational innovation designed to fix billion-dollar clinical trial failures.

A top Virginia cancer practice has been chosen to train US doctors in a breakthrough radiopharmaceutical therapy, a strategic move to break a key training bottleneck.

With an FDA decision just weeks away, Ionis's olezarsen could redefine care for a debilitating condition, marking a pivotal moment for RNA-targeted medicine.

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Barcelona's Ona Therapeutics secures $86.6M to advance its novel antibody-drug conjugates, moving beyond existing treatments to tackle resistant cancers.

As CEO Reshma Kewalramani takes the stage, investors will look for clues on how Vertex plans to pivot from CF dominance to a multi-franchise powerhouse.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

Insulet's latest Omnipod 5 enhancements are more than a software update; they're a strategic move in the diabetes tech race. Here's what it means.

Destination XL faces a perfect storm of declining sales, widening losses, and a crucial merger on the rocks. Can tech and new strategies counter market headwinds?

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

Precision Cardiovascular adds serial entrepreneur Brian Fahey to its board, signaling a push to commercialize its implantable SAW sensor and AI platform.

New data on Syndax Pharma's Revuforj shows a 90% survival rate in a high-risk leukemia group, signaling a potential paradigm shift and major market catalyst.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A new study reveals an 'early warning system' in infant guts, offering a window to combat the atopic march before allergies take hold. Is this the future?